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Imprime PGG (Imprime) in combination with anti-VEGF
monoclonal antibody, bevacizumab has shown promising
clinical efficacy in randomized Phase II clinical trials in
non-small cell lung cancer (NSCLC) patients. Imprime, a
soluble, yeast b-glucan acts as a pathogen associated
molecular pattern (PAMP). As such, Imprime is effi-
ciently and effectively recognized by the cells of innate
immune system-macrophages, monocytes and neutro-
phils- and triggers a coordinated anti-cancer immune
attack in concert with other cancer therapies.
In vitro mechanistic studies using whole blood from
human volunteers have demonstrated that Imprime may
alter the polarization and functionality of monocyte-
derived M2 macrophages, reducing surface expression of
CD163, upregulating PD-L1, driving CD4 and CD8 T cell
expansion and enhancing Th1 polarization. In this study,
we sought to evaluate whether Imprime treatment may
also similarly affect the polarization state of the macro-
phages in vivo, particularly at a tumor site. Athymic nude
mice were injected with the H1299 NSCLC cells. Mice
were randomized to treatment groups (n = 10 per group)
once tumors reached a group mean of ~100mm3. Mice
were treated with vehicle, bevacizumab (5 mg/kg twice
weekly IP), Imprime (1.2mg/mouse twice weekly IV) or
bevacizumab + Imprime. Tumor growth inhibition was
calculated at the end of study (% TGI). Tumor and spleen
tissue was harvested at the end of study and analyzed by
flow cytometry and RT-PCR. CD11b+/CD68+/F4/80+
cells (i.e. murine macrophages) harvested from the spleen
of mice treated with Imprime + bevacizumab showed a
significant increase in protein expression of inducible
nitric oxide synthase (iNOS2) in concert with a significant
decrease in Arginase-1 (Arg-1) when compared to the
same cells harvested from mice treated only with bevaci-
zumab. Furthermore, ex vivo treatment with LPS signifi-
cantly enhanced the production of TNFa in the CD11B
+/CD68+/F4/80+ cells from mice treated with Imprime +
bevacizumab. Remarkably, CD11b+ cells harvested from
the tumor tissue of these mice showed a similar shift
toward an M1-like phenotype, demonstrating significant
increases in iNOS2 and PD-L1 expression, and signifi-
cantly reduced expression of Arg-1, at both the RNA and
protein levels. Furthermore, ELISA data from these
tumors showed a significantly reduced expression of the
potent immunosuppressor, TGFb, when compared to
tumors from mice treated only with bevacizumab, parti-
cularly in the most-responsive tumors (> 50% TGI).
Collectively, these data show for the first time that
Imprime treatment alters the immune microenviron-
ment of a tumor in situ, driving a shift to an M1-like
polarization state.
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